Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?
Identifieur interne : 000673 ( PubMed/Corpus ); précédent : 000672; suivant : 000674Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?
Auteurs : Michael S. Okun ; Daniel WeintraubSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- drug effects : Intestines.
- etiology : Impulse Control Disorders.
- physiology : Intestines.
- therapy : Impulse Control Disorders, Parkinson Disease.
- Deep Brain Stimulation, Humans.
DOI: 10.1002/mds.25735
PubMed: 24243803
Links to Exploration step
pubmed:24243803Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?</title><author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name><affiliation><nlm:affiliation>University of Florida Center for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, Gainesville, Florida.</nlm:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="doi">10.1002/mds.25735</idno><idno type="RBID">pubmed:24243803</idno><idno type="pmid">24243803</idno><idno type="wicri:Area/PubMed/Corpus">000673</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?</title><author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name><affiliation><nlm:affiliation>University of Florida Center for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, Gainesville, Florida.</nlm:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Deep Brain Stimulation</term><term>Humans</term><term>Impulse Control Disorders (etiology)</term><term>Impulse Control Disorders (therapy)</term><term>Intestines (drug effects)</term><term>Intestines (physiology)</term><term>Levodopa (adverse effects)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Intestines</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Impulse Control Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Intestines</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Impulse Control Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Deep Brain Stimulation</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24243803</PMID><DateCreated><Year>2013</Year><Month>12</Month><Day>10</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2014</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>14</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?</ArticleTitle><Pagination><MedlinePgn>1915-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25735</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okun</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>University of Florida Center for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, Gainesville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS044997</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Aug;20(8):1052-5</RefSource><PMID Version="1">15858803</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Psychiatry. 2014 Feb;19(2):145-6</RefSource><PMID Version="1">23337942</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2007 Aug;13(6):369-71</RefSource><PMID Version="1">17049455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2007 Nov 23;318(5854):1309-12</RefSource><PMID Version="1">17962524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Fortschr Neurol Psychiatr. 2008 Jul;76(7):396-401</RefSource><PMID Version="1">18604773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2008 Oct;131(Pt 10):2720-8</RefSource><PMID Version="1">18941146</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2008 Dec;64 Suppl 2:S93-100</RefSource><PMID Version="1">19127573</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CNS Drugs. 2009;23(2):157-70</RefSource><PMID Version="1">19173374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2009 Apr;16(4):493-7</RefSource><PMID Version="1">19236471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 May;132(Pt 5):1376-85</RefSource><PMID Version="1">19346328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 May;65(5):586-95</RefSource><PMID Version="1">19288469</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Aug 15;24(11):1561-70</RefSource><PMID Version="1">19526584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Postgrad Med J. 2009 Nov;85(1009):590-6</RefSource><PMID Version="1">19892894</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2009 Dec;8(12):1140-9</RefSource><PMID Version="1">19909912</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Dec;66(6):817-24</RefSource><PMID Version="1">20035509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2010 Jan;67(1):58-63</RefSource><PMID Version="1">20065130</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S111-5</RefSource><PMID Version="1">20123548</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2010 Jan 14;65(1):135-42</RefSource><PMID Version="1">20152119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2010 May;67(5):589-95</RefSource><PMID Version="1">20457959</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jun 3;362(22):2077-91</RefSource><PMID Version="1">20519680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosurg Focus. 2010 Aug;29(2):E12</RefSource><PMID Version="1">20672914</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Aug 15;25(11):1660-9</RefSource><PMID Version="1">20589879</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Sep;68(3):400-4</RefSource><PMID Version="1">20687121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Oct 30;25(14):2449-53</RefSource><PMID Version="1">20976739</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 Jan;134(Pt 1):36-49</RefSource><PMID Version="1">21059746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Dec;68(6):963-8</RefSource><PMID Version="1">21154480</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 2011 Winter;23(1):56-62</RefSource><PMID Version="1">21304139</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Feb 1;26(2):225-33</RefSource><PMID Version="1">21284039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 Apr;134(Pt 4):969-78</RefSource><PMID Version="1">21349901</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 May;134(Pt 5):1438-46</RefSource><PMID Version="1">21596771</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Addict Biol. 2011 Oct;16(4):620-3</RefSource><PMID Version="1">21762290</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Struct Funct. 2011 Nov;216(4):289-99</RefSource><PMID Version="1">21541715</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurodegener Dis. 2012;9(1):18-24</RefSource><PMID Version="1">21778695</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S80-4</RefSource><PMID Version="1">22166463</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neurochir (Wien). 2011 Dec;153(12):2293-306</RefSource><PMID Version="1">21976235</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2012 Jan;18(1):10-6</RefSource><PMID Version="1">21920794</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(1):e29768</RefSource><PMID Version="1">22295068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2012 May;135(Pt 5):1463-77</RefSource><PMID Version="1">22508959</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(5):e36572</RefSource><PMID Version="1">22629317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurodegener Dis. 2013;11(2):63-71</RefSource><PMID Version="1">23038208</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Feb 26;80(9):792-9</RefSource><PMID Version="1">23325911</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Alcohol Depend. 2013 Apr 1;129(1-2):70-81</RefSource><PMID Version="1">23062870</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2013 Apr 24;33(17):7122-9</RefSource><PMID Version="1">23616522</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Neurosci. 2013 Jul;20(7):964-9</RefSource><PMID Version="1">23712053</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):868-74</RefSource><PMID Version="1">23447648</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Dec;28(14):2007-10</RefSource><PMID Version="1">24123193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Neurol Neurosci Rep. 2007 Jul;7(4):278-89</RefSource><PMID Version="1">17618533</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D046690">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007174">Impulse Control Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007422">Intestines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS535206</OtherID><OtherID Source="NLM">PMC3859686</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25735</ArticleId><ArticleId IdType="pubmed">24243803</ArticleId><ArticleId IdType="pmc">PMC3859686</ArticleId><ArticleId IdType="mid">NIHMS535206</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000673 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000673 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24243803
|texte= Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24243803" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |